1. **DISCUSSION:** Please discuss whether the data presented for hydrocodone and acetaminophen combination drug products support that the nasal route of abuse is relevant for KP201/APAP.

2. **DISCUSSION:** Please discuss whether there are sufficient data to support a finding that KP201 has properties that can be expected to deter abuse commenting on support for deterrent effects for each of the three possible routes of abuse:
   a. Oral
   b. Nasal
   c. Intravenous

3. **VOTE:** Should KP201/APAP be approved for the proposed indication?

4. **VOTE:** If approved, should KP201/APAP be labeled as an abuse-deterrent product?

5. **DISCUSSION:** If you think the product should be approved, discuss the route or routes of abuse for which abuse-deterrent language should be included in the product label.